Journal of Pharmacy Technology最新文献

{"title":"Pharmacy Student Confidence and Practice Readiness After Diabetes Educational Module With CGM Use.","authors":"Allison Hursman, Elizabeth Monson, Allyson Luthi, Jeanne E Frenzel","doi":"10.1177/87551225261433431","DOIUrl":"https://doi.org/10.1177/87551225261433431","url":null,"abstract":"<p><p><b>Background:</b> Pharmacists support diabetes technology in practice, yet formal instruction on continuous glucose monitoring (CGM) in Doctor of Pharmacy (PharmD) curricula is limited. Hands-on learning may build confidence and practice readiness for CGM-enabled care. <b>Objective:</b> To assess the impact of a diabetes education module, paired with short-term personal CGM use on pharmacy students' confidence, beliefs, and reflections related to diabetes care. <b>Methods:</b> Three cohorts of third-year pharmacy students completed pre- and post-surveys surrounding a 2-week diabetes education module delivered within a pharmacy skills laboratory. The intervention included didactic instruction and hands-on stations addressing core components of diabetes management including a personal CGM user wear experience. Quantitative analyses included <i>t</i> tests and analysis of variance. Student reflections were thematically analyzed. <b>Results:</b> Data from 148 student responses (84 pre-intervention; 64 post-intervention) were analyzed as independent samples. Belief scores demonstrated low reliability and remained stable over time (<i>P</i> > 0.05). In contrast, confidence scores showed high reliability and increased significantly following the intervention (mean 2.44 vs 4.50; <i>P</i> < 0.001), with a large effect size. Confidence differed by academic year, while belief scores did not. Qualitative analysis of 159 student responses identified themes of increased knowledge, awareness of glucose impacts, and readiness for pharmacy practice. Limitations include the single-institution setting, unpaired surveys, and reliance on self-reported, short-term outcomes. <b>Conclusion:</b> A diabetes education module incorporating short-term CGM use substantially improved student confidence and yielded practice-relevant insights, while beliefs remained stable. Structured hands-on CGM education may better prepare pharmacy graduates for technology-enabled diabetes care.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261433431"},"PeriodicalIF":1.3,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13099733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nirmatrelvir-Ritonavir Versus Short-Course Remdesivir for Mild COVID-19 in High-Risk Hospitalized Patients: A Propensity Score-Matched Study.","authors":"Taylor D Steuber, Madeline Belk, Blain Thayer, Jonathan Edwards","doi":"10.1177/87551225261436716","DOIUrl":"https://doi.org/10.1177/87551225261436716","url":null,"abstract":"<p><p><b>Background:</b> As coronavirus disease 2019 (COVID-19) has evolved, patients increasingly present with milder disease, raising questions about optimal management of those hospitalized for other conditions, but found to have COVID-19 with high risk of progression. While these patients may traditionally be managed with a 3-day course of remdesivir (RDV) and nirmatrelvir/ritonavir (N/R) in the outpatient setting, these therapies have not been explicitly studied in a similar population, but in the inpatient setting. <b>Objective:</b> To evaluate outcomes with 3-day RDV versus 5-day N/R in high-risk hospitalized patients with mild COVID-19. <b>Methods:</b> This single-center, retrospective, propensity score-matched cohort study included hospitalized adult patients who were found to have mild COVID-19 between January 2023 and December 2023. Patients were grouped by treatment received, including 3-day RDV or 5-day N/R. Baseline characteristics and risk factors for disease progression were collected. Endpoints included incidence of disease progression, need for oxygen and respiratory support, length of stay, 30-day readmission, and mortality. <b>Results:</b> One-hundred and fifty patients were included in the analysis, with 75 in each group. Baseline characteristics between groups were similar. There was no significant difference in the rate of disease progression between the RDV and N/R group (19% vs 11%, respectively; <i>P</i> = 0.166). There was no difference in additional endpoints including hospital length of stay, 30-day readmission, or mortality. <b>Conclusion:</b> There was no significant difference in rates of disease progression or other outcomes among high-risk hospitalized adults with mild COVID-19 treated with RDV or N/R. Larger studies are needed to confirm these findings.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261436716"},"PeriodicalIF":1.3,"publicationDate":"2026-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13092561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elinzanetant: A Nonhormonal Treatment Option for Vasomotor Symptoms Associated With Menopause.","authors":"Lisa Miller","doi":"10.1177/87551225261436749","DOIUrl":"https://doi.org/10.1177/87551225261436749","url":null,"abstract":"<p><p><b>Objective:</b> To review the pharmacology, pharmacokinetics, efficacy, safety, and clinical role of elinzanetant for the treatment of vasomotor symptoms (VMS) associated with menopause. <b>Data Sources:</b> PubMed and Google Scholar were searched for English-language articles published through January 2026 using the terms elinzanetant, NT-814, OASIS, SWITCH, vasomotor symptoms, and menopause. <b>Study Selection and Data Extraction:</b> Phase 2 and phase 3 clinical trials evaluating elinzanetant in postmenopausal women with moderate to severe VMS were included. <b>Data Synthesis:</b> Elinzanetant is a dual neurokinin-1 (NK-1) and neurokinin-3 (NK-3) receptor antagonist targeting hypothalamic pathways involved in thermoregulation. Clinical trials demonstrated statistically significant reductions in VMS frequency and severity compared with placebo. Efficacy was observed as early as week 1 and sustained across treatment periods. Elinzanetant was generally well tolerated, including in long-term studies and in women receiving endocrine therapy for breast cancer. <b>Conclusion:</b> Elinzanetant represents an additional nonhormonal treatment option for menopausal VMS. As a dual NK-1 and NK-3 receptor antagonist, it differs mechanistically from selective NK-3 antagonists and may offer an alternative for patients who are not candidates for hormone therapy.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261436749"},"PeriodicalIF":1.3,"publicationDate":"2026-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13092563/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Signals of Toxicity Associated With Gene Therapy: The Case of Etranacogene Dezaparvovec in the Treatment of Hemophilia B.","authors":"Eleonora Castellana, Maria Rachele Chiappetta","doi":"10.1177/87551225261433445","DOIUrl":"10.1177/87551225261433445","url":null,"abstract":"<p><p><b>Background:</b> Etranacogene dezaparvovec is the first adeno-associated virus (AAV)-based gene therapy approved for the treatment of hemophilia B. Due to its recent market authorization, post-marketing surveillance is essential to characterize its safety profile in real-world clinical practice. <b>Objective:</b> To identify and characterize adverse drug reaction signals associated with etranacogene dezaparvovec using post-marketing pharmacovigilance data. <b>Methods:</b> A disproportionality analysis was performed using reports from the FDA Adverse Event Reporting System (FAERS) from Q1 2023 to Q3 2025, selecting cases in which etranacogene dezaparvovec was reported as the primary suspect drug. Signal detection was conducted with OpenVigil 2.1 using Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Relative Reporting Ratio (RRR), and chi-square statistics. The Evans criteria were applied to identify probable associations. <b>Results:</b> A total of 26 reports including 35 suspected adverse drug reactions were identified. Strong and statistically significant disproportionality signals were observed for hepatic adverse events, particularly increased alanine aminotransferase, aspartate aminotransferase, and liver enzymes, all fulfilling the Evans criteria for probable adverse drug reactions. Moderate but significant signals were also detected for headache, fatigue, and influenza-like illness. <b>Conclusion and Relevance:</b> Post-marketing pharmacovigilance data confirm hepatic toxicity as the predominant safety signal associated with etranacogene dezaparvovec, consistent with clinical trial evidence and the known immunogenic profile of AAV-based gene therapies. These findings support the importance of careful hepatic monitoring in clinical practice and highlight the role of pharmacovigilance in evaluating the real-world safety of innovative gene therapies.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261433445"},"PeriodicalIF":1.3,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13048973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147623348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time to Vancomycin De-Escalation in Pneumonia Patients Screened for MRSA Using Culture vs PCR Testing.","authors":"Kayla N Wilkinson, Megan E Wein, Pamela J McCormick, Bridget M Ott","doi":"10.1177/87551225261429822","DOIUrl":"10.1177/87551225261429822","url":null,"abstract":"<p><p><b>Background:</b> There is no published data comparing time to vancomycin de-escalation for patients with respiratory infections screened for methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) with nasal culture compared to polymerase chain reaction (PCR). <b>Objective:</b> To compare the duration of vancomycin therapy between patients who underwent MRSA testing via culture vs PCR. <b>Methods:</b> This was an Institutional Review Board (IRB) approved, multi-site, retrospective cohort study which included patients receiving vancomycin therapy for the treatment of pneumonia who underwent MRSA screening with either culture or PCR testing. The primary outcome was total days of vancomycin therapy. Secondary outcomes included length of stay (LOS), incidence of acute kidney injury, and time from nasal swab to vancomycin discontinuation. <b>Results:</b> A total of 120 patients met inclusion criteria, with 57 in the culture group and 63 in the PCR group. The median duration of vancomycin was significantly shorter in the PCR group compared to the culture group (0.77 vs 1.80 days; <i>P</i> < 0.001). The median time from nasal swab collection to vancomycin discontinuation was also significantly shorter in the PCR group compared to the culture group (0.29 vs 1.38 days; <i>P</i> < 0.001). There was no difference in the median LOS or the incidence of acute kidney injury (AKI) between groups. <b>Conclusions:</b> This is the first study to directly compare duration of vancomycin therapy as the primary outcome for patients who underwent MRSA screening with nasal culture vs PCR. The use of MRSA PCR testing was associated with a significantly shorter duration of vancomycin therapy in patients with pneumonia when compared to culture-based testing.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261429822"},"PeriodicalIF":1.3,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13035682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Neuropsychiatric Events in Patients Receiving Levetiracetam for Seizure Prophylaxis Following Traumatic Brain Injury.","authors":"Matthew J Ammoscato, Aubrey N Evers, Jacob R Partington, Justin P Reinert","doi":"10.1177/87551225261431159","DOIUrl":"10.1177/87551225261431159","url":null,"abstract":"<p><p><b>Background:</b> Levetiracetam is a soluble ethyl analogue of the nootropic agent piracetam that is utilized primarily for epilepsy treatment. Studies have shown levetiracetam has preferred pharmacokinetic and pharmacodynamic properties compared to phenytoin, however, limited data exist regarding neuropsychiatric side effects. <b>Purpose:</b> To evaluate the incidence of neuropsychiatric events in patients under the age of 75 and over the age 75 years receiving levetiracetam for seizure prophylaxis following traumatic brain injury (TBI). <b>Methods:</b> This study was a retrospective cohort analysis conducted at the University of Toledo Medical Center (UTMC) between January 1, 2023, and March 15, 2025. Inclusion criteria required adults aged >18 years old who had been admitted to the surgical intensive care unit (SICU) and received levetiracetam for seizure prophylaxis following a TBI. The primary study outcome was to assess the incidence of neuropsychiatric events attributed to levetiracetam. Secondary outcomes included levetiracetam dose/route, seizure occurrence, time to onset of neuropsychiatric event, SICU length of stay and duration of levetiracetam treatment. <b>Results:</b> There were 55 patients included in the study. For the primary endpoint, two patients (3.6%) experienced a neuropsychiatric event. There were 14 patients (25.5%) with a history of psychiatric disorders, and just 1 of those patients experienced a neuropsychiatric event while receiving levetiracetam. <b>Conclusions:</b> Levetiracetam is a well-tolerated antiepileptic agent for patients requiring seizure prophylaxis post TBI and did not demonstrate a significant incidence of neuropsychiatric events in this evaluation.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261431159"},"PeriodicalIF":1.3,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13005756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147504199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between a Shortage of Normal Saline and In-Hospital Outcomes Among Individuals With Febrile Neutropenia.","authors":"Allie E Stacks, Logan A Russell, Erin R Weeda","doi":"10.1177/87551225261429321","DOIUrl":"10.1177/87551225261429321","url":null,"abstract":"<p><p><b>Background:</b> Normal saline (NS) is a vital resource used to care for patients with febrile neutropenia (FN). A 2017 shortage in NS driven by Hurricane Maria raised concerns about patient outcomes. <b>Objective:</b> This study aimed to evaluate the impact of this shortage on in-hospital mortality and the length of stay (LOS) among adults with FN. <b>Methods:</b> The National Inpatient Sample database was used to identify adult FN encounters. Two cohorts were defined: a pre-shortage group (November 2016-March 2017) and a shortage group (November 2017-March 2018). In-hospital mortality was the primary outcome, and LOS was secondary. <b>Results:</b> We identified 19 425 encounters with FN in the dataset, 9584 occurring pre-shortage and 9841 occurring during the shortage. Cohorts were similar in age, sex, and race. Small but statistically significant differences were observed in primary payer distribution (<i>P</i> = 0.022) and hospital size (<i>P</i> = 0.037). In-hospital mortality was similar between cohorts (7.1% vs 6.9). Mean LOS was also similar during the pre-shortage vs shortage periods (10.1 ± 12.7 vs 10.2 ± 13.0 days). Adjusted analyses demonstrated no differences in mortality (aOR = 1.01; 95% CI = 0.90-1.13) or LOS (mean difference = 0.1 days; 95% CI = -0.14 to 0.38). <b>Conclusion:</b> Mortality and LOS were stable across pre-shortage and shortage periods in patients with FN despite the national NS shortage. While such shortages may disproportionately affect patients with conditions that rely heavily on supportive fluids and rapid intravenous medication administration, this study did not observe statistically significant negative impacts on patient outcomes.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261429321"},"PeriodicalIF":1.5,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13004712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147498949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cyclobenzaprine Reimagined: Clinical Insights Into Tonmya for Fibromyalgia.","authors":"Erin St Onge, Phuoc Tyler Bui, Haven Rogers, Isabel Guerrero, Bradley Phillips","doi":"10.1177/87551225261426559","DOIUrl":"10.1177/87551225261426559","url":null,"abstract":"<p><p><b>Objective:</b> To review the efficacy, safety, and tolerability of a sublingual formulation of cyclobenzaprine for the treatment of fibromyalgia. <b>Data Sources:</b> A literature search was conducted through PubMed and DrugBank using the following terms: cyclobenzaprine, fibromyalgia, sublingual, Tonmya, and TNX-102 SL. <b>Study Selection and Data Extraction:</b> Articles describing the pharmacology, pharmacokinetics, efficacy, safety, and/or tolerability of sublingual cyclobenzaprine were included in this review. <b>Data Synthesis:</b> Cyclobenzaprine is a tricyclic antidepressant like agent which exhibits sedative and muscle relaxant effects in the treatment of fibromyalgia. Clinical trials have demonstrated improvements in daily pain scores compared with placebo. Common adverse events associated with this agent include oral hypoesthesia, oral paresthesia, and abnormal taste. <b>Conclusions:</b> Pharmacologic agents receive a weak recommendation for use in the treatment guidelines and include agents such as duloxetine, pregabalin, tramadol, amitriptyline, and a nonsublingual formulation of cyclobenzaprine. Tonmya, the newest agent approved for fibromyalgia, provides clinicians with an additional treatment option in a convenient dosage form for this potentially debilitating condition.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261426559"},"PeriodicalIF":1.3,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12975529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147444224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Pancreatitis Associated with Propofol in a Patient with End-Stage Renal Disease: Diagnostic Challenges and Confounding Factors.","authors":"Waldo-Rodríguez Itzayana Guadalupe, Arriaga-García Francisco Javier, Romano-Moreno Silvia, Medellín-Garibay Susanna Edith, Martínez-Núñez Juan Manuel, Castro-Pastrana Lucila Isabel, Milán-Segovia Rosa Del Carmen","doi":"10.1177/87551225261422609","DOIUrl":"10.1177/87551225261422609","url":null,"abstract":"<p><p><b>Objective:</b> Acute pancreatitis is an inflammatory disorder of the pancreas with diverse etiologies, including rare drug-induced causes such as propofol. Propofol-associated acute pancreatitis has been linked to hypertriglyceridemia; however, causal attribution is particularly challenging in patients with chronic kidney disease, due to metabolic disturbances and overlapping clinical features. <b>Case:</b> We report the case of a 49-year-old female with end-stage chronic kidney disease admitted with septic shock requiring mechanical ventilation and continuous sedation with propofol infused at 70 mg/h. After 8 days of therapy, she developed progressive hypertriglyceridemia followed by clinical and biochemical findings consistent with acute pancreatitis. Common etiologies were excluded, and the temporal relationship supported a probable adverse drug reaction. <b>Discussion/Conclusions:</b> This case highlights the diagnostic and causal complexity of acute pancreatitis in critically ill patients with advanced chronic kidney disease and underscores the importance of vigilant metabolic monitoring and multidisciplinary medication review during propofol therapy.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261422609"},"PeriodicalIF":1.3,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12935577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147326454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vancomycin Overdose and Infusion Rate Error Leading to a Mixed Anticholinergic-Type Syndrome in a Hemodialysis Patient: A Case Report.","authors":"Waldo-Rodríguez Itzayana Guadalupe, Arriaga-García Francisco Javier, Romano-Moreno Silvia, Medellín-Garibay Susanna Edith, Martínez-Núñez Juan Manuel, Castro-Pastrana Lucila Isabel, Milán-Segovia Rosa Del Carmen","doi":"10.1177/87551225261417925","DOIUrl":"10.1177/87551225261417925","url":null,"abstract":"<p><p><b>Objective:</b> To describe a mixed anticholinergic-type syndrome not previously associated with vancomycin in a patient with end-stage renal disease on hemodialysis, highlighting the impact of dosing and infusion rate errors. <b>Case:</b> A 61-year-old man with stage 5 chronic kidney disease on hemodialysis was admitted to the internal medicine unit for a catheter-related infection. Vancomycin was initiated at 1 g every 12 hours, infused at 16.6 mg/min. After four doses, the patient developed transient amaurosis, tachycardia, hyperthermia, xerostomia, xeroderma, confusion, agitation, and panic, consistent with a mixed anticholinergic-type syndrome. Symptoms resolved after discontinuation of vancomycin and subsequent hemodialysis. <b>Discussion/Conclusions:</b> This case demonstrates a definite association between vancomycin overdose with rapid infusion and the development of a mixed anticholinergic-type syndrome in a patient on hemodialysis. These findings underscore the importance of careful dose adjustment and strict control of infusion rates in advanced renal disease.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225261417925"},"PeriodicalIF":1.3,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12935586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147326400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}